A modified Essen Stroke Risk Score for predicting recurrent ischemic stroke at one year

Xia, Ling; Yan, Sha; Shen, Bo; Yang, Xu

doi:10.1080/01616412.2018.1428389

Cited by 13 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite advancements in medical therapy, the risk of recurrent ischemic stroke treated with optimal medication therapy remains between 6.5% and 20% per year in Asia. [18][19][20][21] The incidence rate per 100 person-years of recurrent stroke in our study (0.543) was lower than that reported by Ogata and Omori (6.486 and 10.672, respectively).…”

Section: Recurrence Stroke After Ablation In Patients With Prior Stcontrasting

confidence: 73%

Recurrent ischemic stroke in patients with atrial fibrillation ablation and prior stroke: A study based on etiological classification

Fukamizu

Hojo

Kitamura

et al. 2019

Journal of Arrhythmia

View full text Add to dashboard Cite

Background: Different subtypes of ischemic stroke may have different risk factors, clinical features, and prognoses. This study investigated the incidence and mode of stroke recurrence in patients with a history of stroke who underwent atrial fibrillation (AF) ablation. Methods:Of 825 patients who underwent AF ablation from 2006 to 2016, 77 patients (9.3%, median age 69 years) with a prior ischemic stroke were identified.Patients were classified as those with prior cardioembolic (CE) stroke (n = 55) and those with prior non-CE stroke (n = 22). The incidence and pattern of stroke recurrence were investigated. Results:The incidence of asymptomatic AF (54.5% vs 22.7%; P = .011) and left atrial volume (135.8 mL vs 109.3 mL; P = .024) was greater in the CE group than in the non-CE group. Anticoagulation treatment was discontinued at an average of 28.1 months following the initial ablation in 34 (44.2%) patients. None of the patients developed CE stroke during a median 4.1-year follow-up. In the non-CE group, 2 patients experienced recurrent non-CE stroke (lacunar infarction in 1 and atherosclerotic stroke in 1); however, AF was not observed at the onset of recurrent ischemic stroke. Conclusions:In patients with a history of stroke who underwent catheter ablation for AF, the incidence of recurrent stroke was 0.54/100 patient-years. The previous stroke in these patients may not have been due to AF in some cases; therefore, a large-scale prospective study is warranted to identify the appropriate antithrombotic therapy for the prevention of potentially recurrent stroke.

show abstract

Section: Recurrence Stroke After Ablation In Patients With Prior Stcontrasting

confidence: 73%

Recurrent ischemic stroke in patients with atrial fibrillation ablation and prior stroke: A study based on etiological classification

Fukamizu

Hojo

Kitamura

et al. 2019

Journal of Arrhythmia

View full text Add to dashboard Cite

show abstract

“…It is extremely important that clinicians are able to predicate the risk of END in patients with acute ischemic stroke in the early stages in order to choose an appropriate treatment method. Although many predictive models have been developed to project short-term or long-term functional outcomes of the disease and the risk of recurrence in patients (29)(30)(31), the WORSEN score (8) was the only one specifically developed for detection of END in acute ischemic stroke patients. Our study aimed to externally validate the WORSEN score in our population, and our findings indicated that it had a good predictive value for severe END with a sensitivity of 70.91%, specificity of 83.95%, and an the AUC of WORSEN score of 0.82 (95%CI 0.78-0.86).Fittingly, our findings were in line with prior studies.…”

Section: Discussionmentioning

confidence: 99%

External Validation of the WORSEN Score for Prediction the Deterioration of Acute Ischemic Stroke in a Chinese Population

Chen

et al. 2020

Front. Neurol.

View full text Add to dashboard Cite

Background: Early neurological deterioration (END) has been recognized as a serious neurological complication after acute ischemic stroke. However, to date, the WORSEN score was the only one scoring system specifically developed to detect END events in acute ischemic stroke patients. The purpose of this study was to investigate the WORSEN score's utility in China, and to determine the potential predictors of END in acute stroke patients. Methods: Consecutive patients with acute ischemic stroke admitted to the Department of Neurology, Aerospace Center Hospital between March 2015 to February 2017 were recruited into the study's cohort and divided into two groups: patients with and without END. END was defined as either an increase in two or more NIHSS points, an increment of at least one point in motor power or a description of fluctuating of clinical symptoms in medical reports during the first 7 days after admission. Severe END was defined as an increase of NIHSS ≥ 4 points from baseline during the first 7 days after admission. Results: Three hundred fifty four patients with acute ischemic stroke were enrolled in the present study and 67.5% were male. END occurred in 90 of these patients and severe END occurred in 55 of these patients. Logistic regression analysis showed that an initial NIHSS score ≥8, diameter of infarction, striatocapsular infarction, and TOAST type of large arterial atherosclerosis were independent predictors for END. The area under the ROC curve (AUC) of the WORSEN score for the prediction of END was 0.80 (95%CI 0.75-0.84), with a sensitivity of 62.22%, a specificity of 88.26%, positive predictive values of 64.37% and negative predictive values of 87.27%. Meanwhile, the AUC of the WORSEN score for the prediction of severe END was 0.82 (95%CI 0.78-0.86), with a sensitivity of 70.91%, specificity of 83.95%, positive predictive values of 44.83% and negative predictive values of 94.01%. Conclusion: END is a relatively common neurological complication in patients with acute ischemic stroke. Our findings showed that the WORSEN score had a good predictive value for identifying patients with END in a Chinese population. Moving forward, multi-center studies are required for further validations

show abstract

“…Brain tissue ischemia and hypoxia cause irreversible damage to some nerve functions. Under the combined action of multiple risk factors, recurrent stroke causes the brain tissue to suffer from hypoperfusion and oxidative stress again, further aggravating the nerve injury [ 20 ]. However, it has not been clarified whether the risk factors for recurrent and first-ever stroke are completely similar, and there are few studies on the severity and short-term prognosis of recurrent ischemic stroke.…”

Section: Discussionmentioning

confidence: 99%

sLOX-1: A Molecule for Evaluating the Prognosis of Recurrent Ischemic Stroke

Zheng

Huang

et al. 2021

Neural Plasticity

View full text Add to dashboard Cite

Several clinical parameters and biomarkers have been proposed as prognostic markers for stroke. However, it has not been clarified whether the risk factors affecting the prognosis of patients with recurrent and first-ever stroke are similar. In this study, we aimed to explore the relationship between soluble lectin-like oxidized low-density lipoprotein receptor 1 (sLOX-1) levels and the prediction of the functional outcome in patients with recurrent and first-ever stroke. A total of 266 patients with recurrent and first-ever stroke, who underwent follow-up for 3 months, were included in this study. Plasma samples were collected within 24 h after onset. The results showed that biomarkers for the prognosis of patients with recurrent stroke were different from that of those with first-ever stroke. sLOX-1 levels were correlated with modified Rankin Scale scores of patients with recurrent stroke alone ( r = 0.3232 , p = 0.001 ). sLOX-1 levels were also associated with an increased risk of unfavorable outcomes in patients with recurrent stroke with an adjusted odds ratio of 1.489 (95% confidence interval, 1.204–1.842, p < 0.0001 ). Combining the risk factors showed greater accuracy for prognosis, yielding a sensitivity of 93.2% and a specificity of 75%, with an area under the curve of 0.916, evaluated by the receiver operating characteristic curve. These findings suggest that the diagnosis and prognosis are different between patients with recurrent stroke and those with first-ever stroke, and sLOX-1 level is an independent prognostic marker in patients with recurrent stroke.

show abstract

A modified Essen Stroke Risk Score for predicting recurrent ischemic stroke at one year

Cited by 13 publications

References 36 publications

Recurrent ischemic stroke in patients with atrial fibrillation ablation and prior stroke: A study based on etiological classification

Recurrent ischemic stroke in patients with atrial fibrillation ablation and prior stroke: A study based on etiological classification

External Validation of the WORSEN Score for Prediction the Deterioration of Acute Ischemic Stroke in a Chinese Population

sLOX-1: A Molecule for Evaluating the Prognosis of Recurrent Ischemic Stroke

Contact Info

Product

Resources

About